Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus glucocorticoid plus cyclophosphamide for adult idiopathic membranous nephropathy
ChiCTR2600131511Phase 4Completed
- Sponsor
- Yiwu Central Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab, prednisone and cyclophosphamide in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Yiwu Central Hospital. Primary endpoints: serum albumin at 12 months, 24-hour urine protein quantification at 12 months and 1 more. Started Dec 2023; status: completed.
02
Drugs
rituximabprednisonecyclophosphamide
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2600131511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131511.